nmd670
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 21, 2023 (NCT05794139)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Chloride channel protein 1INHIBITOR
CLCN1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06482437 | Phase 2 | Sep 30, 2024 | NMD Pharma A/S |
| NCT06414954 | Phase 2 | May 16, 2024 | NMD Pharma A/S |
| NCT05794139 | Phase 2 | Sep 21, 2023 | NMD Pharma A/S |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NMD Pharma A/S | For profit | 3 | 3 | 1 | 2023 |
1 organizations
Page 1 / 1